Trexquant Investment LP Allovir, Inc. Transaction History

Trexquant Investment LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$4.7 - $9.98 $319,524 - $678,480	67,984 New	67,984 $348,000
Q2 2022 Aug 11, 2022	BUY	$3.26 - $7.06 $49,460 - $107,114	15,172 New	15,172 $59,000
Q1 2022 May 13, 2022	SELL	$6.75 - $13.52 $240,394 - $481,501	-35,614 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$12.94 - $25.99 $460,845 - $925,607	35,614 New	35,614 $461,000
Q2 2021 Aug 12, 2021	SELL	$19.44 - $25.06 $218,077 - $281,123	-11,218 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$20.81 - $45.5 $233,446 - $510,419	11,218 New	11,218 $263,000

44.6M

14.9K

200

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $40.9M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.